Cell/Gene Tx channel feed

Bris­tol-My­ers is mak­ing a bee-line to the FDA with pos­i­tive liso-cel da­ta — but is it too late in the CAR-T game?

6 years ago
R&D

Pa­tient #9 has been a con­cern, but Sang­amo and Pfiz­er are bull­ish about win­ning the marathon he­mo­phil­ia A gene ther­a­py race

6 years ago
R&D

J&J team shows off 'break­through' BC­MA CAR-T da­ta, and that could cause a big headache at blue­bird and Bris­tol-My­ers

6 years ago
R&D

With FDA re­view of its gene ther­a­py un­der­way, Fer­ring's $570M spin­out de­liv­ers in PhI­II blad­der can­cer read­out

6 years ago
R&D

No­var­tis, Ver­tex out­line big gene ther­a­py plans — fu­el­ing a glob­al boom

6 years ago

In a land­mark first glimpse of hu­man da­ta from Ver­tex, CRISPR/Cas9 gene ther­a­py sig­nals ear­ly ben­e­fit

6 years ago
R&D

Sarep­ta picks up a slate of pre­clin­i­cal gene ther­a­py pro­grams, seed­ing new Stride­Bio deal with $48M up­front

6 years ago
Deals

FDA puts Sol­id Bio’s lead gene ther­a­py pro­gram on hold — again — af­ter an­oth­er pa­tient is hurt by SGT-001

6 years ago
R&D

De­cry­ing 'ar­bi­trary and capri­cious' ac­tion, Re­genxBio sues FDA over clin­i­cal holds on gene ther­a­py

6 years ago
FDA+

Re­genxBio runs in­to par­tial hold for an­ti-VEGF gene ther­a­py as FDA in­ves­ti­gates de­liv­ery de­vice

6 years ago
FDA+

Ther­mo Fish­er hooks gut on­to its gene ther­a­py pipeline, inks new col­lab­o­ra­tion pact

6 years ago

No­var­tis takes a hit as FDA or­ders a hold on Zol­gens­ma tri­als in wake of fresh safe­ty con­cerns

6 years ago
Pharma
FDA+

Sean Park­er helps cre­ate a CRISPRed cell ther­a­py 2.0 play — and he’s got a high-pro­file set of lead­ers on the team

6 years ago
Financing
Startups

Ex­clu­sive: GSK’s Hal Bar­ron al­lies with Rick Klaus­ner’s $600M cell ther­a­py start­up, look­ing to break new ground blitz­ing sol­id tu­mors

6 years ago
Deals

Ness Berming­ham looks to lead the wave of RNA edit­ing at new At­las up­start Ko­r­ro Bio

6 years ago
Startups

Ear­ly func­tion­al da­ta on limb gir­dle pa­tients buoy ex­pec­ta­tions for Sarep­ta's gene ther­a­py

6 years ago
R&D

Re­gen­eron dou­bles down on part­ner Adicet's gam­ma delta T cell tech in $80M fi­nanc­ing

6 years ago
Financing

San Fran­cis­co biotech has its heart in heart fail­ure — and $92M in the bank

6 years ago
Startups

ARC-T? Al­ter­na­tive CAR-T start­up bags $85M for clin­i­cal quest to redi­rect 'blind hunter' T cells

6 years ago
Startups

Neoanti­gen play­er PACT Phar­ma woos Tim Moore from Kite to run tech­ni­cal ops

6 years ago
People

The time is now: John Cox as­sumes CEO post at Flag­ship-backed Torque, steer­ing cell ther­a­py to clin­i­cal tri­als

6 years ago
People

Reg­u­la­tors throw up an­oth­er hur­dle to Roche’s $4.3B Spark ac­qui­si­tion as ques­tions per­co­late over he­mo­phil­ia mar­ket dom­i­na­tion

6 years ago
Deals

No­var­tis ac­cus­es 2 AveX­is founders of al­ter­ing da­ta, stonewalling probe — but ex-CSO blasts back

6 years ago
Pharma
FDA+

Zol­gens­ma did­n't cause an in­fant death, AveX­is ex­ecs say as they spot­light long-term da­ta

6 years ago
R&D
Pharma
First page Previous page 49505152535455 Next page Last page
A service from the Financial Times